Product Information
ROFLUMILAST 250 MCG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $1.9069 per EA under NDC 00904749371. Its NADAC has been published 28 times since Dec 17, 2025.
Strength
250 ug/1
Manufacturer
Major PharmaceuticalsNDC
00904749371
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
ROFLUMILASTApproval Type
Generic (ANDA)
FDA Application
ANDA208256On Market Since
10/27/2025
Pharmacological Classes
Price Statistics
The NADAC for ROFLUMILAST 250 MCG TABLET has been published 28 times since Dec 17, 2025, and over the history we have for it it has declined 16.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9069 per EA |
|---|---|
| All-time high | $2.2887 (Jan 14, 2026) |
| All-time low | $1.9069 (Jun 17, 2026) |
| 52-week high | $2.2887 |
| 52-week low | $1.9069 |
| Median price | $2.1436 |
| Average price | $2.1254 |
| Largest weekly change | -8.5% (Apr 22, 2026) |
| Weeks tracked | 28 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 4 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 4 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ROFLUMILAST 250 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Major Pharmaceuticals, is $1.9069 per EA (NDC 00904749371), effective Jun 24, 2026.
How has the price of ROFLUMILAST 250 MCG TABLET changed over time?
Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 16.7%. It has been tracked across 28 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?
Since Dec 17, 2025, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.9069 (Jun 17, 2026) to a high of $2.2887 (Jan 14, 2026), with a median of $2.1436 per EA.
Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?
4 NADAC-published products share the same active ingredient, strength, and dosage form as ROFLUMILAST 250 MCG TABLET, but none are currently priced below it.
Who manufactures ROFLUMILAST 250 MCG TABLET?
ROFLUMILAST 250 MCG TABLET (NDC 00904749371) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.
Related Drugs
Same classification